GlobeNewswire by notified

Moleac’s NeuroAiD™II Improves Post-Concussion Symptoms, Quality of Life, and Mood after a Mild Traumatic Brain Injury

Share
  • With its targeted multimodal approach, NeuroAiD™II offers a broad range of therapeutic benefits to TBI patients.
  • NeuroAiD™II was well-tolerated by TBI patients with a favourable safety profile.

SINGAPORE, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Moleac announced promising results from the SAMURAI double-blind study in patients with mild traumatic brain injury (mTBI) receiving a 6-month course of NeuroAiD™II. In the study, the NeuroAiD™II group showed significant improvement in their post-concussion symptoms, quality of life and mood, compared to those in the placebo group.   

Presented by Professor Valery Feigin at the World Congress of Neurology, last October in Montreal, these results expand the list of therapeutic benefits of NeuroAiD™II observed in previous clinical trials conducted on TBI patients, and confirm its favourable safety profile1, 2, 3.

In the SAMURAI study, mTBI patients underwent a series of tests assessing various types of impairments and their recovery over time. For cognition, a self-assessment was done by the patient using a computerized scale, the Computerized Neurocognitive Assessment-Vital Signs (CNS-VS). For post-concussion symptoms, quality of life and mood, the tests were conducted by the investigators using 3 different scales: the Rivermead Post-Concussion Symptoms Questionnaire (RPQ), the Quality of Life after Brain Injury (QOLIBRI) scale, and the Hospital Anxiety and Depression Scale (HADS) respectively.

While the improvement of CNS-VS self-assessment score was not different between groups at the 6-month and 9-month time points with a surprising improvement in the placebo group, the assessments performed by investigators showed highly statistically significant benefits of NeuroAiD™II over placebo at both 6-month and 9-month time point, and on the 3 scales. These positive results reflect the durable benefits provided by NeuroAiD™II, even after treatment discontinuation.

“Persistent symptoms following a TBI can severely affect a patient’s day-to-day life. Following the pilot study BRAINS1, we are further encouraged by SAMURAI, illustrating the wide spectrum of benefits provided by NeuroAiD™II in helping patients to achieve a holistic recovery in the physical, cognitive and emotional aspects,” said David Picard, CEO of Moleac.

Professor Feigin added, “The trial showed that although NeuroAid did not significantly improved cognitive functioning in post mild traumatic brain injury individuals, it significantly reduced various other complaints associated with the injury (lightheadedness, headaches, dizziness, anxiety, depression etc) and improved overall health-related quality of life after mTBI. I have no doubts that, when indicated, millions of individuals with mTBI could benefit from using NeuroAid to alleviate their post-injury symptoms.”

TBI is an injury caused by a mechanical impact on the brain or skull or by the penetration of objects into the skull. Damage and death of brain cells often lead to neurological and cognitive deficits. The global incidence of TBI is about 50 to 60 million new events each year, with mTBI representing more than 90% of all TBI4. After one year, 20% to over 30% of mTBI patients continue to experience clinically significant sequelae and over 80% remain symptomatic5. Persistent deficits can highly affect one’s ability to live independently5. Moreover, these physical, cognitive, and emotional symptoms may persist for a long time6,7. This represents an urgent need for TBI treatment to not only treat physical symptoms but to positively impact the psychological and emotional well-being of the patients.

Dr. Sylvain Durrleman, Head of Medical Affairs at Moleac, commented, “Recovery from TBI is complex and multidimensional. With its multimodal mechanism of action, NeuroAiD™II is well-suited for TBI recovery, showing positive clinical impacts on physical symptoms and important parameters of the quality of life.”

On how the results may contribute to clinical practice in the disease area, Dr. Durrleman added, “We hope the results are meaningful to both healthcare practitionners and patients, further demonstrating the benefit of NeuroAiD™II in promoting recovery processes.”

For more information, please visit www.neuroaid.com.

About NeuroAiD™II

NeuroAiD™II is a scientifically-researched formulation containing 9 natural herbal ingredients, recommended for patients with established deficits to boost their recovery after a traumatic brain injury.

About Moleac

Moleac is a biopharmaceutical company committed to helping patients and families reconnect with their lives. Headquartered in Singapore, we are dedicated to developing scientifically proven innovative formulations that bridge therapeutic gaps and address unmet needs of patients with neurological conditions such as stroke, traumatic brain injuries and dementia.

Moleac’s flagship product NeuroAiD™II benefits more than 40,000 patients in over 35 countries every year.

For more information, please visit www.moleac.com.

Contact Details

Name of Press Contact: Clement Dif

Phone: +65 6211 3710

Email: communication@moleac.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Response to media reports about data theft27.2.2024 10:34:27 CET | Press release

Over the past days Danish media have reported stories about a theft of source code involving Netcompany Denmark. We can confirm one single incident involving a simple theft of Netcompany Denmark source code and user manuals. We can refute that the incident is a ransomware attack. The data theft has not affected Netcompany or our customer’s operations and services. We know how the theft has occurred, the extent of the theft, and that the theft resides around source code and user manuals for Netcompany tools. Since the simple theft was discovered, we have worked in close collaboration with authorities and have implemented additional mitigating actions to ensure a continued high level of security in our production systems landscape. We have taken necessary precautions that ensure the stolen files cannot be used to gain unauthorized access to any system. In Denmark, Netcompany runs several government core systems however, the stolen files cannot be used to gain unauthorised access or compr

IDEX Biometrics ASA – Invitation to presentation of fourth quarter and preliminary results for 202327.2.2024 10:30:00 CET | Press release

Oslo, Norway – 27 February 2024 - IDEX Biometrics will publish its interim report for the fourth quarter and preliminary results for 2023 on Thursday 29 February at 08:00 CET. The interim report will also be available on the company’s website: www.idexbiometrics.com. Webcast: There will be a webcast on Thursday 29 February 2024 at 09:00 CET. The presentation will be held by Vince Graziani, Chief Executive Officer, and Catharina Ekløf, Chief Commercial Officer. The presentation file will be available at www.idexbiometirics.com, and the webcast presentation can be viewed using the following link: https://idexbiometrics.videosync.fi/q4-2023/ For further information contact: Marianne Bøe, Head of Investor Relations E-mail: marianne.boe@idexbiometrics.com Tel: + 47 918 00186 About IDEX Biometrics IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring

Belships ASA: Mandatory notification of trade27.2.2024 10:15:00 CET | Press release

Oslo, 27 February 2024 AS Torinitamar, which is closely associated with Lars Christian Skarsgård, CEO in Belships ASA, has today acquired 50 000 shares in Belships ASA at a price of NOK 20.61 per share. After the acquisition Skarsgård and AS Torinitamar combined own 950 000 shares and 5 000 000 options in Belships ASA. See further details in the attached form. This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19. Attachment Notification of transaction by Primary Insider

Placeringsforeningen Nykredit Invest suspenderer handel med alle afdelinger27.2.2024 10:12:04 CET | pressemeddelelse

Nykredit Portefølje Administration A/S har anmodet Nasdaq Copenhagen om suspension af fonde, som administreres af Nykredit Portefølje Administration A/S. Det skyldes, at det grundet tekniske udfordringer ikke er muligt at stille NAV. Suspensionen vil blive ophævet, når det igen er muligt at stille korrekte priser. Følgende afdeling er omfattet af suspensionen: ISINAfdelingOrderbook CodeDK0060231777Nykredit Invest Danske FokusaktierNYKDFA Eventuelle spørgsmål vedrørende denne meddelelse kan rettes til npa.pm@nykredit eller JNA@nykredit.dk Med venlig hilsen Nykredit Portefølje Administration A/S Tage Fabrin-Brasted

HiddenA line styled icon from Orion Icon Library.Eye